Item 2.02 Results of Operations and Financial Condition.

On January 9, 2020, Castle Biosciences, Inc. (the "Company") issued a press release announcing certain preliminary performance results for the fourth quarter of 2019 and for the year ended December 31, 2019. A copy of the press release is attached hereto as Exhibit 99.1.

The information contained or incorporated in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

On January 9, 2020, the Company made available via its website, www.castlebiosciences.com, an updated slide presentation for use in meetings with investors, analysts and others. A copy of the slide presentation is attached hereto as Exhibit 99.2.

The information contained or incorporated in this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

By filing this Current Report on Form 8-K, including Exhibit 99.2 attached hereto, and furnishing this information, the Company makes no admission as to the materiality of such information. The information contained in this report is intended to be considered in the context of the Company's filings with the Securities and Exchange Commission ("SEC") and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.




Item 9.01  Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number    Description
99.1        Press Release issued January 9, 2020.
99.2        Slide Presentation dated January 9, 2020.

© Edgar Online, source Glimpses